Obesity transforms fat tissue into a pro-inflammatory organ releasing leptin, TNF-α, and IL-6, which activates NF-κB signaling and polarizes immune cells toward inflammation. In spondyloarthritis patients, this creates systemic immunometabolic priming that amplifies disease activity at spinal attachment sites through the IL-23/IL-17 pathway. Obese patients show higher disease activity scores, faster joint damage progression, and reduced response to biologic therapies, potentially due to subtherapeutic drug levels in larger body masses. This mechanistic framework represents a significant advancement in understanding autoimmune-metabolic interactions. The finding that obesity acts as a modifiable disease amplifier opens therapeutic avenues beyond traditional immunosuppression. Weight loss interventions, including GLP-1 receptor agonists and Mediterranean diets, demonstrate promise for restoring inflammatory balance and improving drug efficacy. However, this synthesis relies heavily on observational data, and the proposed mechanisms require validation through controlled trials. The integration of metabolic optimization with immunotherapy could revolutionize spondyloarthritis management, shifting focus from symptom control to addressing root inflammatory drivers through lifestyle medicine.